Ivermectin for COVID-19
4th treatment shown to reduce risk in
August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.
No treatment is 100% effective.
Protocols combine treatments.
Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
Hussain et al., 11 Dec 2020, preprint, 3 authors.
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
International Journal of Molecular & Immuno Oncology, doi:10.25259/ijmio_30_2020
is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
References
Caly, Druce, Catton, Jans, Wagstaff, e FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cortiula, Pettke, Bartoletti, Puglisi, Helleday, Managing COVID-19 in the oncology clinic and avoiding the distraction effect, Ann Oncol
Hussain, Shuayb, Rahman, Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh, Int J Mol Immuno Oncol, doi:10.25259/IJMIO_30_2020
Hussman, Cellular and Molecular Pathways of COVID-19 and Potential Points of erapeutic Intervention, Front Pharmacol
Maurya, A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients
DOI record:
{
"DOI": "10.25259/ijmio_30_2020",
"ISSN": [
"2456-3994"
],
"URL": "http://dx.doi.org/10.25259/IJMIO_30_2020",
"alternative-id": [
"10.25259/IJMIO_30_2020"
],
"article-number": "27",
"author": [
{
"affiliation": [
{
"name": "Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh,"
}
],
"family": "Hussain",
"given": "Syed Md Akram",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Vancouver Prostate Centre, Vancouver General Hospital, The University of British Columbia, Vancouver, Canada,"
}
],
"family": "Shuayb",
"given": "Md",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Emerging Infections Program, IDD, International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh,"
}
],
"family": "Rahman",
"given": "Mahmudur",
"sequence": "additional"
}
],
"container-title": "International Journal of Molecular and Immuno Oncology",
"container-title-short": "IJMIO",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"ijmio.com"
]
},
"created": {
"date-parts": [
[
2020,
12,
2
]
],
"date-time": "2020-12-02T12:39:43Z",
"timestamp": 1606912783000
},
"deposited": {
"date-parts": [
[
2023,
3,
20
]
],
"date-time": "2023-03-20T06:29:39Z",
"timestamp": 1679293779000
},
"indexed": {
"date-parts": [
[
2023,
3,
20
]
],
"date-time": "2023-03-20T07:12:57Z",
"timestamp": 1679296377498
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2021,
1,
8
]
]
},
"language": "en",
"link": [
{
"URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "10894",
"original-title": [],
"page": "27-29",
"prefix": "10.25259",
"published": {
"date-parts": [
[
2021,
1,
8
]
]
},
"published-online": {
"date-parts": [
[
2021,
1,
8
]
]
},
"publisher": "Scientific Scholar",
"reference": [
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "publisher",
"first-page": "104787",
"journal-title": "Antiviral Res",
"key": "10.25259/IJMIO_30_2020/ref-2",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.3389/fphar.2020.01169",
"article-title": "Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention",
"author": "Hussman",
"doi-asserted-by": "publisher",
"first-page": "1169",
"journal-title": "Front Pharmacol",
"key": "10.25259/IJMIO_30_2020/ref-4",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.1016/j.annonc.2020.03.286",
"article-title": "Managing COVID-19 in the oncology clinic and avoiding the distraction effect",
"author": "Cortiula",
"doi-asserted-by": "publisher",
"first-page": "553",
"journal-title": "Ann Oncol",
"key": "10.25259/IJMIO_30_2020/ref-5",
"volume": "31",
"year": "2020"
}
],
"reference-count": 3,
"references-count": 3,
"relation": {},
"resource": {
"primary": {
"URL": "https://ijmio.com/outcome-of-ivermectin-and-doxycycline-in-cancer-patients-with-coronavirus-disease-2019-a-positive-experience-in-bangladesh/"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.25259/crossmark_policy",
"volume": "6"
}